Company news

Igc Pharma, Inc. (AMEX:IGC) news

Igc Pharma, Inc. news releases on 6ix. Latest, Sep 28, 2026: IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4…

Igc Pharma, Inc. (AMEX:IGC) news

Press releases & updates

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

IGC Pharma CEO and Principal Financial Officer Purchase More Than $1.15 Million of Common Stock Directly from the Company

IGC Pharma (NYSE: IGC) CEO and CFO Acquire More Than 4.2 Million Shares

IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference

IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness

New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

IGC Pharma Announces Equity Research Update by Alliance Global Partners

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."